• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
CUA guidelines on the management of non-muscle invasive bladder cancer.加拿大泌尿外科协会非肌层浸润性膀胱癌管理指南。
Can Urol Assoc J. 2015 Sep-Oct;9(9-10):E690-704. doi: 10.5489/cuaj.3320. Epub 2015 Oct 13.
2
Comparison of Guidelines on Non-Muscle Invasive Bladder Cancer (EAU, CUA, AUA, NCCN, NICE).非肌肉浸润性膀胱癌指南（欧洲泌尿外科学会、加拿大泌尿外科学会、美国泌尿外科学会、美国国立综合癌症网络、英国国家卫生与临床优化研究所）比较
Bladder Cancer. 2016 Jan 7;2(1):27-36. doi: 10.3233/BLC-150034.
3
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines.欧洲泌尿外科学会肌层浸润性和转移性膀胱癌指南：2020 年指南摘要。
Eur Urol. 2021 Jan;79(1):82-104. doi: 10.1016/j.eururo.2020.03.055. Epub 2020 Apr 29.
4
2023 UPDATE - Canadian Urological Association guideline: Management of cystic renal lesions Prior to original publication (March 2017), this guideline underwent review by the CUA Guidelines Committee, CUA members at large, and the CUA Executive Board. The 2023 updates were app roved by the CUA Guidelines Committee and CUA Executive Board.2023年更新——加拿大泌尿外科协会指南：囊性肾病变的管理 在最初发布（2017年3月）之前，本指南经过了加拿大泌尿外科协会指南委员会、广大加拿大泌尿外科协会成员以及加拿大泌尿外科协会执行委员会的审查。2023年的更新内容已获加拿大泌尿外科协会指南委员会和加拿大泌尿外科协会执行委员会批准。
Can Urol Assoc J. 2023 Jun;17(6):162-174. doi: 10.5489/cuaj.8389.
5
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.欧洲泌尿外科学会非肌肉浸润性膀胱癌（TaT1 和原位癌）指南 - 2019 年更新版。
Eur Urol. 2019 Nov;76(5):639-657. doi: 10.1016/j.eururo.2019.08.016. Epub 2019 Aug 20.
6
Management of low-risk and intermediate-risk non-muscle-invasive bladder carcinoma.低风险和中风险非肌层浸润性膀胱癌的管理
Hematol Oncol Clin North Am. 2015 Apr;29(2):219-25, vii. doi: 10.1016/j.hoc.2014.11.001.
7
Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer.2016 年更新版 EAU 肌层浸润性和转移性膀胱癌临床实践指南。
Eur Urol. 2017 Mar;71(3):462-475. doi: 10.1016/j.eururo.2016.06.020. Epub 2016 Jun 30.
8
Guideline of guidelines: non-muscle-invasive bladder cancer.指南之指南：非肌层浸润性膀胱癌
BJU Int. 2017 Mar;119(3):371-380. doi: 10.1111/bju.13760. Epub 2017 Jan 24.
9
EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines.EAU 指南：肌层浸润性和转移性膀胱癌：2013 年指南摘要。
Eur Urol. 2014 Apr;65(4):778-92. doi: 10.1016/j.eururo.2013.11.046. Epub 2013 Dec 12.
10
Non-muscle-invasive Bladder Cancer: Side-by-Side Guideline Comparison.非肌肉浸润性膀胱癌：指南并排比较。
Eur Urol Focus. 2023 Nov;9(6):954-956. doi: 10.1016/j.euf.2023.05.004. Epub 2023 Jun 10.

引用本文的文献

1
Metastasis development in non-muscle-invasive bladder cancer.非肌层浸润性膀胱癌中的转移发展
Nat Rev Urol. 2024 Nov 20. doi: 10.1038/s41585-024-00963-y.
2
Epirubicin and Non-Muscle Invasive Bladder Cancer Treatment: A Systematic Review.表柔比星与非肌层浸润性膀胱癌的治疗：一项系统评价
J Clin Med. 2024 Jun 27;13(13):3789. doi: 10.3390/jcm13133789.
3
Routine Surveillance of Upper Urinary Tract Imaging for Diagnosing Upper Urinary Tract Urothelial Cancer Recurrence in Patients with Nonmuscle Invasive Bladder Cancer.非肌层浸润性膀胱癌患者上尿路成像的常规监测用于诊断上尿路尿路上皮癌复发
Adv Urol. 2024 May 21;2024:5894288. doi: 10.1155/2024/5894288. eCollection 2024.
4
BCG induced lower urinary tract symptoms during treatment for NMIBC-Mechanisms and management strategies.卡介苗在非肌层浸润性膀胱癌治疗期间引起的下尿路症状——机制与管理策略
Front Neurosci. 2024 Jan 8;17:1327053. doi: 10.3389/fnins.2023.1327053. eCollection 2023.
5
The p38-MITOGEN-ACTIVATED PROTEIN KINASE Signaling Pathway Is Involved in Extract-Induced Inhibition of the Proliferation of Human Bladder Cancer BFTC-905 Cells via G1/G0 Arrest and Causes Apoptosis In Vitro.p38丝裂原活化蛋白激酶信号通路通过G1/G0期阻滞参与提取物诱导的人膀胱癌BFTC-905细胞增殖抑制并在体外引发细胞凋亡。
Pharmaceuticals (Basel). 2023 Sep 22;16(10):1338. doi: 10.3390/ph16101338.
6
Uncommon but Clinically Significant: Bacillus Calmette-Guerin (BCG) Infection of the Urinary Tract and its Impact on Quality of Life.罕见但具有临床意义：卡介苗（BCG）感染泌尿道及其对生活质量的影响。
Am J Case Rep. 2023 Aug 4;24:e940375. doi: 10.12659/AJCR.940375.
7
Thiolated Mesoporous Silica Nanoparticles as an Immunoadjuvant to Enhance Efficacy of Intravesical Chemotherapy for Bladder Cancer.巯基化介孔硅纳米颗粒作为免疫佐剂增强膀胱癌膀胱内化疗的疗效。
Adv Sci (Weinh). 2023 Mar;10(7):e2204643. doi: 10.1002/advs.202204643. Epub 2023 Jan 13.
8
Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Abridged version.加拿大泌尿外科协会非肌层浸润性膀胱癌管理指南 - 简版
Can Urol Assoc J. 2021 Aug;15(8):230-239. doi: 10.5489/cuaj.7487.
9
A Retrospective Analysis of Clinical and Pathologic Characteristics of Recurrent Bladder Tumor in a Tertiary Hospital in Addis Ababa, Ethiopia.埃塞俄比亚亚的斯亚贝巴一家三级医院复发性膀胱癌的临床和病理特征回顾性分析。
Ethiop J Health Sci. 2021 Jul;31(4):779-784. doi: 10.4314/ejhs.v31i4.12.
10
Recent Advances in the Management of Patients with Non-Muscle-Invasive Bladder Cancer Using a Multidisciplinary Approach: Practical Recommendations from the Spanish Oncology Genitourinary (SOGUG) Working Group.采用多学科方法管理非肌层浸润性膀胱癌患者的最新进展：西班牙泌尿生殖肿瘤学（SOGUG）工作组的实用建议
Cancers (Basel). 2021 Sep 23;13(19):4762. doi: 10.3390/cancers13194762.

本文引用的文献

1
Randomized trial of narrow-band versus white-light cystoscopy for restaging (second-look) transurethral resection of bladder tumors.随机试验：窄带光与白光膀胱镜用于经尿道膀胱肿瘤切除术后的复查（二次探查）。
Eur Urol. 2015 Apr;67(4):605-8. doi: 10.1016/j.eururo.2014.06.049. Epub 2014 Jul 17.
2
Diagnosis and management of intradiverticular bladder tumours.腔内型膀胱肿瘤的诊断与治疗。
Nat Rev Urol. 2014 Jul;11(7):383-90. doi: 10.1038/nrurol.2014.131. Epub 2014 Jun 17.
3
Contemporary cost-effectiveness analysis comparing sequential bacillus Calmette-Guerin and electromotive mitomycin versus bacillus Calmette-Guerin alone for patients with high-risk non-muscle-invasive bladder cancer.当代成本效益分析：比较序贯卡介苗和电动丝裂霉素与单独使用卡介苗治疗高危非肌层浸润性膀胱癌患者的效果
Cancer. 2014 Aug 15;120(16):2424-31. doi: 10.1002/cncr.28731. Epub 2014 Apr 18.
4
Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy.卡介苗菌株差异对膀胱癌免疫治疗的临床结局有影响。
Eur Urol. 2014 Oct;66(4):677-88. doi: 10.1016/j.eururo.2014.02.061. Epub 2014 Mar 12.
5
Blue-light cystoscopy in the evaluation of non-muscle-invasive bladder cancer.蓝光膀胱镜检查在非肌层浸润性膀胱癌评估中的应用
Ther Adv Urol. 2014 Feb;6(1):25-33. doi: 10.1177/1756287213510590.
6
Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.卡介苗治疗失败的患者可能是非肌层浸润性膀胱癌，原因可能是泌尿科医生未能检测到上尿路和尿道的尿路上皮癌。
Eur Urol. 2014 Apr;65(4):825-31. doi: 10.1016/j.eururo.2013.09.049. Epub 2013 Oct 9.
7
Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer.前瞻性随机临床试验：六氨基己酸光动力辅助经尿道膀胱肿瘤切除术（TURBT）联合单次膀胱内丝裂霉素 C 治疗与传统白光 TURBT 联合丝裂霉素 C 治疗新诊断的非肌层浸润性膀胱癌。
BJU Int. 2013 Dec;112(8):1096-104. doi: 10.1111/bju.12355.
8
The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin.经膀胱内卡介苗治疗的非肌肉浸润性膀胱癌患者，再次经尿道电切术对复发率和进展率的影响。
J Urol. 2014 Feb;191(2):341-5. doi: 10.1016/j.juro.2013.08.022. Epub 2013 Aug 20.
9
Side effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG.卡介苗（BCG）治疗中高危 Ta、T1 期膀胱乳头状癌的副作用：EORTC 泌尿生殖系统癌症组比较三分之一剂量与全剂量以及 1 年与 3 年维持 BCG 的随机 3 期研究结果。
Eur Urol. 2014 Jan;65(1):69-76. doi: 10.1016/j.eururo.2013.07.021. Epub 2013 Jul 24.
10
Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature.氨基酮戊酸光动力膀胱镜检查在非肌层浸润性膀胱癌诊断和随访中的应用：对当前文献的批判性评价。
Eur Urol. 2013 Oct;64(4):624-38. doi: 10.1016/j.eururo.2013.07.007. Epub 2013 Jul 19.

CUA guidelines on the management of non-muscle invasive bladder cancer.

作者信息

Kassouf Wassim, Traboulsi Samer L, Kulkarni Girish S, Breau Rodney H, Zlotta Alexandre, Fairey Andrew, So Alan, Lacombe Louis, Rendon Ricardo, Aprikian Armen G, Siemens D Robert, Izawa Jonathan I, Black Peter

机构信息

Division of Urology, McGill University, Montreal, QC;

Division of Urology, University of Toronto, Toronto, ON;

出版信息

Can Urol Assoc J. 2015 Sep-Oct;9(9-10):E690-704. doi: 10.5489/cuaj.3320. Epub 2015 Oct 13.

DOI:10.5489/cuaj.3320
PMID:26664503
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4662433/
Abstract
摘要